Iris Pharma is a world-leading Contract Research Organization (CRO), dedicated to preclinical and clinical research in ophthalmology. Since 1989, they have been offering ophthalmologic drug and device development services to pharmaceutical and biotechnology companies worldwide.

Their focus on the eye allows us to be at the forefront of this field and to help our clients to pass their product through the testing and regulatory process in a rapid and cost-effective manner, allowing them to market their drug and device faster.

At Iris Pharma, quality is a state of mind. Their Quality Assurance program is designed to ensure that your studies are performed in compliance with GLP, GCLP and ICH-GCP requirements, guidelines (FDA, OECD, etc) and local regulatory laws.

The CRO has expertise in all ophthalmic indications – from the ocular surface to the posterior segment of the eye – and supports customers, newcomers or experts in ophthalmology, ranging from small start-up companies to large pharmaceutical companies in moving forward products that directly or indirectly affect eye health.

In addition to a wide portfolio of services such as proof of concept studies in animal models, GLP preclinical studies, clinical trials and post-market studies, bioanalytical testing, cellular and molecular biology assays, Iris Pharma also offer consulting services to help customers determine the best indication and the best route for molecules and products in development.

To support more than 400 customers worldwide, Iris Pharma maintain a GLP-accredited laboratory for preclinical research and bioanalytical testing and conducts high-quality clinical trials in accordance with ICH GCP guidelines.

–  Therapeutic areas: Ophthalmology

–  Based in: La Gaude (FRANCE)

–  Employees: 11 – 50

–  Created in: 1989